Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641201 | 0.86 | EGLN1 (0.54) | EGLN3HIF1AHPGDEGLN1 | |
| SCHEMBL1641577 | 0.84 | HIF1A (0.45) | EGLN3HIF1AEGLN1 | |
| SCHEMBL1642177 | 0.83 | EGLN3 (0.61) | EGLN3HIF1AHPGDEGLN1 | |
| SCHEMBL1642705 | 0.78 | EGLN1 (0.48) | EGLN3HIF1AHPGDEGLN1 | |
| SCHEMBL1642648 | 0.78 | EGLN1 (0.46) | EGLN3HIF1AHPGDEGLN1 | |
| SCHEMBL1641920 | 0.78 | EGLN1 (0.48) | EGLN3EGLN1 | |
| SCHEMBL1642807 | 0.77 | TOP2A (0.49) | EGLN3HIF1AEGLN1 | |
| SCHEMBL1643005 | 0.77 | EGLN1 (0.46) | EGLN3HIF1AEGLN1 | |
| SCHEMBL1641131 | 0.77 | EGLN1 (0.59) | EGLN3EGLN1 | |
| SCHEMBL1642454 | 0.75 | EGLN3 (0.59) | EGLN3HIF1AHPGDEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885HIF1A 4/4885HPGD 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.